Aptevo Therapeutics And Alligator Bioscience Announce Interim Data From Phase 1 Trial Of ALG.APV-527 Monotherapy; 60% Of Evaluable Patients Achieved Stable Disease In Solid Tumor Study
Portfolio Pulse from Benzinga Newsdesk
Aptevo Therapeutics and Alligator Bioscience have announced interim data from a Phase 1 trial of their monotherapy ALG.APV-527. The trial showed that 60% of evaluable patients achieved stable disease in a study focused on solid tumors.
September 16, 2024 | 12:12 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Aptevo Therapeutics reported positive interim results from a Phase 1 trial of ALG.APV-527, with 60% of patients achieving stable disease in solid tumors. This could boost investor confidence in the company's pipeline.
The positive interim results from the Phase 1 trial of ALG.APV-527 suggest potential efficacy in treating solid tumors, which could enhance Aptevo's product pipeline and attract investor interest, likely leading to a short-term positive impact on APVO's stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80